Journal of Cystic Fibrosis · 2016 · 25 citations · 13 references
MedicineClinical SciencesPharmacotherapyGastroenterologyPulmonary Function TestingPulmonologyAirway DiseasesAirway DisordersAirway ObstructionCystic FibrosisCystic Fibrosis PharmacotherapyGastroesophageal Reflux DiseaseCftr Gene MutationsCystic Fibrosis GeneticsExtraesophageal Reflux SymptomsIvacaftor TherapyLung Function DeclineLung Function TestingMutationReflux Symptom Index
BACKGROUND: Extra-oesophageal reflux (EOR) may lead to microaspiration in patients with cystic fibrosis (CF), a probable cause of deteriorating lung function. Successful clinical trials of ivacaftor highlight opportunities to understand EOR in a real world study. METHODS: Data from 12 patients with CF and the G551D mutation prescribed ivacaftor (150mg bd) was collected at baseline, 6, 26 and 52weeks. The changes in symptoms of EOR were assessed by questionnaire (reflux symptom index (RSI) and Hull airway reflux questionnaire (HARQ)). RESULTS: Six patients presented EOR at baseline (RSI >13; median 13; range 2-29) and 5 presented airway reflux (HARQ >13; median 12; range 3 to 33). Treatment with ivacaftor was associated with a significant reduction of EOR symptoms (P<0∙04 versus baseline) denoted by the reflux symptom index and Hull airway reflux questionnaire. CONCLUSION: Ivacaftor treatment was beneficial for patients with symptoms of EOR, thought to be a precursor to microaspiration.
13
Steven M. Rowe, Sonya L. Heltshe, Tanja Gonska et al. · American Journal of Respiratory and Critical Care Medicine · 2014 · 498 citations
Cough Hypersensitivity Syndrome: A Distinct Clinical Entity
Alyn H. Morice, Shoaib Faruqi, Caroline Wright et al. · Lung · 2010 · 235 citations · Full text